Phase Ib Study Tests Safe Dosage of Copanlisib, Nivolumab, and Rituximab Combination

Tycel Phillips, MD discusses his study that will test the maximum safe dosage and response rate of a combination of drugs for relapsed/refractory indolent lymphoma.